Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,346.00
(
0.04%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 178982

Monday, 06/09/2014 9:36:02 AM

Monday, June 09, 2014 9:36:02 AM

Post# of 257302
MRK-IDIX deal dispels two longstanding biotech canards:

Canard #1
Big Pharma won’t pay a large premium to the market
price of a small or medium-sized biotech company.

Fact: MRK is paying a 239% premium to
IDIX’s closing price on Friday (i.e. the
buyout price is 339% of Friday’s close).

Canard #2
News of a biotech buyout always leaks.

Fact: There was no leakage in this case.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today